scholarly article | Q13442814 |
P50 | author | JoAnn E. Manson | Q6204013 |
Vanessa M Barnabei | Q56462140 | ||
Dorothy S Lane | Q91756399 | ||
Barbara B Cochrane | Q92707865 | ||
Joseph J Larson | Q92889428 | ||
Marcia L. Stefanick | Q109542605 | ||
Judith K. Ockene | Q113389547 | ||
Margery L Gass | Q114309265 | ||
P2093 | author name string | Charles Mouton | |
P2860 | cites work | Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 |
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial | Q29615226 | ||
Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative | Q30435044 | ||
Factors associated with successful discontinuation of hormone therapy | Q33571609 | ||
Symptom experience after discontinuing use of estrogen plus progestin | Q34433581 | ||
Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition | Q34810941 | ||
The impact of multimorbidity on sexual function in middle-aged and older women: beyond the single disease perspective | Q35023884 | ||
Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009 | Q35068765 | ||
Sexual activity and satisfaction in healthy community-dwelling older women | Q35634439 | ||
Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders | Q36746505 | ||
The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society | Q36793595 | ||
Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial | Q37163204 | ||
Sexual dysfunction among older adults: prevalence and risk factors from a nationally representative U.S. probability sample of men and women 57-85 years of age. | Q37374996 | ||
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials | Q37658616 | ||
A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women | Q39346649 | ||
Hormone use and patient concerns after the findings of the Women's Health Initiative | Q39364121 | ||
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group | Q39513392 | ||
Prevalence of genitourinary and other climacteric symptoms in 61-year-old women | Q43330304 | ||
Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative | Q43458097 | ||
Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey | Q43669097 | ||
Ovarian androgen production in postmenopausal women | Q44897806 | ||
Menopausal symptoms after the discontinuation of long-term hormone replacement therapy in women under 60: a 3-year follow-up. | Q45157245 | ||
Prevalence and impact of vaginal symptoms among postmenopausal women | Q46395492 | ||
Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women | Q46468162 | ||
Sexual problems and distress in United States women: prevalence and correlates. | Q51675955 | ||
Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. | Q51689212 | ||
Relationship between hypoactive sexual desire disorder and aging. | Q51778117 | ||
Genitourinary syndrome of menopause | Q56929516 | ||
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society | Q87323247 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 252-264 | |
P577 | publication date | 2017-11-06 | |
P1433 | published in | Menopause | Q6817295 |
P1476 | title | Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials | |
P478 | volume | 25 |
Q93186260 | Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women | cites work | P2860 |
Search more.